Spero Therapeutics
Ed Sopp has extensive experience in quality assurance in the pharmaceutical industry. Ed started their career in 1989 at Damon Biotech in a production role. Ed then worked as a QC employee at Abbott Biotech and Repligen Corporation before joining GelTex Pharmaceuticals as a QC/QA employee in 1995. In 2003, they became a QA Associate Director at Genzyme, followed by QA Director roles at Nitromed, Proteon Therapeutics, and Concert Pharmaceuticals. From 2015 to 2018, they served as the Senior Director of Quality Assurance at Kala Pharmaceuticals. Currently, they are the Vice President/Head of Quality Assurance at Spero Therapeutics, overseeing all drug development candidates' quality assurance and compliance with regulatory guidelines.
Ed Sopp attended Bridgewater State University from 1985 to 1989, where they earned a Bachelor of Science degree. Ed also attended St. Johns Prep, although the specific dates are unknown.
This person is not in any offices
Spero Therapeutics
2 followers
Spero Therapeutics (Nasdaq: SPRO) is a multi-asset pre-commercial stage biopharmaceutical company in Cambridge, Mass. We are highly committed to advancing novel treatment approaches for bacterial infections with a world-class team of biotechnological and biopharmaceutical experts. The company has a pipeline of novel and highly differentiated antibacterial and rare disease product candidates focused on patients' unmet needs with multi-drug resistant (MDR) bacterial infections.